CERo Therapeutics Holdings has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $9,400,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, CERo Therapeutics Holdings is raising $9,400,000.00 in new funding. About CERo Therapeutics Holdings: CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California. Our mission is to discover, translate, and deliver pioneering cuOur mission is to discover, translate, and deliver pioneering curative cell therapies that incorporate multiple forms of tumor clearance into single T cells.rative cell therapies that incorporate multiple forms of tumor clearance into single T cells. We are pioneering a new generation of autologous T-cell-based therapies that uniquely combine attributes of macrophages and dendritic cells of the innate immune system with those of T cells (adaptive immune system) for treatment of both hematologic and solid tumor cancers. This integrated approach draws on recent advances in synthetic and T cell biology with the intent to increase the curative potential and safety profile of current therapies.
To learn more about CERo Therapeutics Holdings, visit http://www.cero.bio/
Contact:
Daniel Corey, Chief Technical Officer
650-407-2376
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.